Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Search Results: 1 - 3 of 3 matches for " Abozeid AMANSOUR "
All listed articles are free for downloading (OA Articles)
Page 1 /3
Display every page Item
Effect of Pelvic Floor Electrical Stimulation and Biofeedback on the Recovery of Urinary Continence after Radical Prostatectomy
Mohammed Taher AHMED,Ashraf Hassan MOHAMMED,Abozeid AMANSOUR
Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi , 2012,
Abstract: bjective: Urinary incontinence (UI) is one of the most distressing postoperative problems of radical prostatectomy (RP) and negatively affects the quality of life (QOL). We assessed the effect of pelvic muscle exercises (PME), electrical stimulation (ES) and biofeedback (BFB) on UI after RP. Materials and Methods: 80 patients, who underwent RP, were randomized into three groups. Group I (n=26) received instructions about PME, group II (n=26) received ES and group III (n=28) received ES plus BFB. The treatment was started one week after catheter removal, twice a week for 12 weeks. The evaluation of continence was performed at time 0, 6, 12 weeks, and 24 weeks during follow-up, using the 24-hour pad test and the QOL using the incontinence impact questionnaire -7 (IIQ-7). Results: The mean leakage weight became significantly lower (p<0.05) in group III than in groups II and I starting at 6 weeks until 24 weeks of follow-up. A significant difference (p<0.05) between the groups in terms of percentage of continent patients was achieved from 12 weeks (71.42%, 53.85% and 34.62%) to 24 weeks (96.43%, 76.92% and 65.38%) for groups III, II and I, respectively. Conclusion: Early, noninvasive therapy with ES and BFB has a significant positive effect on the duration and the degree of UI and QOL. Turk J Phys Med Re-hab 2012;58:170-6.
Assessment of Behavior Abnormalities of Corticosteroids in Children with Nephrotic Syndrome
Doaa Mohammed Youssef,Mohamed Mohamed Abdelsalam,Ali Mohamed Abozeid,Usama Mahmoud Youssef
ISRN Psychiatry , 2013, DOI: 10.1155/2013/921253
Abstract: Introduction. The objective of this work was to define the frequency and severity of steroid related behavioral side effects in children with steroid sensitive idiopathic nephrotic syndrome (SSNS) during Treatment for relapse. Methods. 30 pediatric patients with steroid sensitive nephrotic syndrome were studied; known as SSNS at complete remission or low dose of Prednisolone and have relapse on follow up. All children in this study were subjected to full history taking, thorough clinical examination, assessment socioeconomic standard, and assessment of pediatric quality of life, a battery of psychometric tests included pediatric anxiety, depression, and aggression scores. Results. Our results revealed that there are highly significant increase in the mean values of anxiety, depression and aggression among cases starts to appear on week one and extends to three, five and seven weeks compared to baseline. In the seventh week of follow up cases show significant positive correlation between prednisone doses and mean values of anxiety and depression scores and aggression. Conclusion. we concluded that all studied children with SSNS often experience significant problems with anxiety, depression, and increased aggression during high dose steroid therapy. 1. Introduction Since Edward Kendall isolated cortisone in the late 1930 and Philip Hench first used it to treat rheumatoid arthritis in 1948. Corticosteroids have become the corner stone of therapy for many neurologic, respiratory, gastrointestinal, renal, endocrine, hematologic, neoplastic, rheumatologic, dermatologic, ophthalmic, and allergic conditions. More than 10 million new corticosteroid prescriptions are filled each year, up to 0.9% of the general population and as many as 7% of hospitalized patients receiving oral corticosteroid therapy at any given point [1]. Although a powerful therapeutic option, corticosteroids are associated with serious adverse effects, both physiologic and psychiatric. While the somatic adverse effects of corticosteroid therapy have been extensively researched and widely described, the neuropsychiatric adverse effects have received less attention. Moreover, the etiology and pathogenesis of these brain effects remain poorly understood The neuropsychiatric adverse effects of corticosteroids are complex, unpredictable, and often severe, ranging across most categories of psychopathology Mood liability, anxiety symptoms, cognitive impairments, behavioral disturbances, or psychotic features can present alone or in combination [2]. The aim of this study is to evaluate the
Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Cara J. Westmark, Pamela R. Westmark, Kenneth J. O'Riordan, Brian C. Ray, Crystal M. Hervey, M. Shahriar Salamat, Sara H. Abozeid, Kelsey M. Stein, Levi A. Stodola, Michael Tranfaglia, Corinna Burger, Elizabeth M. Berry-Kravis, James S. Malter
PLOS ONE , 2011, DOI: 10.1371/journal.pone.0026549
Abstract: Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS, binds to and controls the postsynaptic translation of amyloid β-protein precursor (AβPP) mRNA. Cleavage of AβPP can produce β-amyloid (Aβ), a 39–43 amino acid peptide mis-expressed in Alzheimer's disease (AD) and Down syndrome (DS). Aβ is over-expressed in the brain of Fmr1KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of AβPP/Aβ rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1KO mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Aβ1–42 was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal levels were somewhat increased, suggesting that Aβ is sequestered in the brain. Evolving therapies directed at reducing Aβ in AD may be applicable to FXS and Aβ may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy.
Page 1 /3
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.